VYNDAMAX (tafamidis)
AMYLOIDOSIS AGENTS - PROTEIN STABILIZERS · TRANSTHYRETIN-RELATED AMYLOID CARDIOMYOPATHY
Parke-Davis Pfizer
Drug class
Amyloidosis Agents - Protein Stabilizers
Amyloidosis agents that act as protein stabilizers are targeted small-molecule therapeutics designed to prevent amyloid fibril formation. Read more about Amyloidosis Agents - Protein Stabilizers
2 drugs in this class 2 manufacturers
Drugs in Amyloidosis Agents - Protein Stabilizers
ATTRUBY (acoramidis HCl)
AMYLOIDOSIS AGENTS - PROTEIN STABILIZERS · TRANSTHYRETIN-RELATED AMYLOID CARDIOMYOPATHY
BRIDGEBIO PHARM
Filter & compare in the drug finder →
Opens the drug finder with Amyloidosis Agents - Protein Stabilizers preselected. Add indication or manufacturer filters there.
Amyloidosis agents that act as protein stabilizers are targeted small-molecule therapeutics designed to prevent amyloid fibril formation.
These agents function by binding selectively to the thyroxine-binding sites of circulating precursor proteins—predominantly the transthyretin tetramer—kinetically stabilizing the native quaternary structure and preventing its dissociation into misfolded, amyloidogenic monomers.
Their primary therapeutic role is in managing transthyretin amyloidosis, including hereditary and wild-type forms, to halt the progression of amyloid cardiomyopathy and peripheral polyneuropathy.
By inhibiting upstream amyloid deposition, they help decrease disease-related cardiovascular hospitalizations, mitigate neurologic decline, and improve overall survival.
-
nih.gov
Amyloidosis agents that act as protein stabilizers are targeted small-molecule therapeutics designed to prevent amyloid fibril formation
-
fda.gov
These agents function by binding selectively to the thyroxine-binding sites of circulating precursor proteins—predominantly the transthyretin tetramer—kinetically stabilizing the native quaternary structure and preventing its dissociation into misfolded, amyloidogenic monomers
-
nih.gov
These agents function by binding selectively to the thyroxine-binding sites of circulating precursor proteins—predominantly the transthyretin tetramer—kinetically stabilizing the native quaternary structure and preventing its dissociation into misfolded, amyloidogenic monomers
-
fda.gov
Their primary therapeutic role is in managing transthyretin amyloidosis, including hereditary and wild-type forms, to halt the progression of amyloid cardiomyopathy and peripheral polyneuropathy
-
fda.gov
Their primary therapeutic role is in managing transthyretin amyloidosis, including hereditary and wild-type forms, to halt the progression of amyloid cardiomyopathy and peripheral polyneuropathy By inhibiting upstream amyloid deposition, they help decrease disease-related cardiovascular hospitalizations, mitigate neurologic decline, and improve overall survival
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.